Prokidney (PROK) Cash from Operations (2021 - 2026)
Prokidney (PROK) reported Cash from Operations of 41684000.0 for Q1 2026, down 40.86% year-over-year from 70486453.03 in Q1 2025, and down 28.21% on a QoQ basis from 32513000.0 in Q4 2025.
Prokidney (PROK) has 6 years of Cash from Operations data on file, last reported at 41684000.0 in Q1 2026.
- Quarterly Cash from Operations fell 40.86% year-over-year to 41684000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 132209000.0 (down 9.0% YoY) and the FY2025 annual result came in at 120117000.0, up 4.93% from the prior year.
- Cash from Operations fell to 41684000.0 in Q1 2026 per PROK's latest filing, from 32513000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 14916000.0 in Q2 2023 and bottomed at 41684000.0 in Q1 2026.
- The 5-year median for Cash from Operations is 25992000.0 (2023), against an average of 26782941.18.
- The widest annual swing landed in 2022, when Cash from Operations sank 11202073.91%; it then jumped 35.22% in 2023.
- Tracing PROK's Cash from Operations over 5 years: stood at 15761000.0 in 2022, then plunged by 61.06% to 25384000.0 in 2023, then gained by 4.78% to 24171000.0 in 2024, then sank by 34.51% to 32513000.0 in 2025, then fell by 28.21% to 41684000.0 in 2026.
- Per Business Quant, the three latest PROK Cash from Operations figures stand at 41684000.0 (Q1 2026), 32513000.0 (Q4 2025), and 26596000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.43 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 1.08 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 70.50 Mn |
| 10 | Prokidney | 259.72 Mn | 1.55 Bn | - | -41.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -41.68 Mn |
| Mar 31, 2026 | -41.68 Mn |
| Dec 31, 2025 | -32.51 Mn |
| Dec 31, 2025 | -32.51 Mn |
| Sep 30, 2025 | -26.60 Mn |
| Sep 30, 2025 | -26.60 Mn |
| Jun 30, 2025 | -31.42 Mn |
| Jun 30, 2025 | -31.42 Mn |
| Mar 31, 2025 | -29.59 Mn |
| Mar 31, 2025 | -29.59 Mn |
| Dec 31, 2024 | -24.17 Mn |
| Dec 31, 2024 | -24.17 Mn |
| Sep 30, 2024 | -29.24 Mn |
| Sep 30, 2024 | -29.24 Mn |
| Jun 30, 2024 | -38.29 Mn |
| Jun 30, 2024 | -38.29 Mn |
| Mar 31, 2024 | -34.65 Mn |
| Mar 31, 2024 | -34.65 Mn |
| Dec 31, 2023 | -25.38 Mn |
| Dec 31, 2023 | -25.38 Mn |
| Sep 30, 2023 | -23.78 Mn |
| Sep 30, 2023 | -23.78 Mn |
| Jun 30, 2023 | -14.92 Mn |
| Jun 30, 2023 | -14.92 Mn |
| Mar 31, 2023 | -25.99 Mn |
| Mar 31, 2023 | -25.99 Mn |
| Dec 31, 2022 | -15.76 Mn |
| Dec 31, 2022 | -15.76 Mn |
| Sep 30, 2022 | -22.84 Mn |
| Sep 30, 2022 | -22.84 Mn |
| Jun 30, 2022 | -23.03 Mn |
| Jun 30, 2022 | -23.03 Mn |
| Mar 31, 2022 | -15.46 Mn |
| Mar 31, 2022 | -15.46 Mn |
| Dec 31, 2021 | -1.21 Mn |
| Dec 31, 2021 | -1.21 Mn |
| Sep 30, 2021 | -1.14 Mn |
| Sep 30, 2021 | -1.14 Mn |
| Jun 30, 2021 | -19,837.00 |
| Jun 30, 2021 | -19,837.00 |
| Mar 31, 2021 | -138.00 |
| Mar 31, 2021 | -138.00 |